Navigation Links
Acorda Therapeutics Presents Data from its Phase 3 Study of,Fampridine-SR in Multiple Sclerosis at the American Academy of,Neurology Meeting

ng Acorda Therapeutics' ability to successfully market and sell Zanaflex Capsules, the risk of unfavorable results from future studies of Fampridine-SR, delays in obtaining or failure to obtain FDA approval of Fampridine-SR, competition, the ability to obtain additional financing to support Acorda Therapeutics' operations, unfavorable results from its preclinical programs, and failure to protect its intellectual property or to defend against the intellectual property claims of others. These and other risks are described in greater detail in Acorda Therapeutics' filings with the Securities and Exchange Commission. Acorda Therapeutics may not actually achieve the goals or plans described in its forward-looking statements, and investors should not place undue reliance on these statements. Acorda Therapeutics disclaims any intent or obligation to update any forward-looking statements as a result of developments occurring after the date of this press release.

About Acorda Therapeutics

Acorda Therapeutics is a biotechnology company developing therapies for SCI, MS and related nervous system disorders. The Company's marketed products include Zanaflex Capsules(TM) (tizanidine hydrochloride), a short-acting drug for the management of spasticity. For full prescribing information, please go to www.zanaflexcapsules.com. Acorda's lead clinical stage product, Fampridine-SR, recently completed a Phase 3 study in people with MS. The Company's pipeline includes a number of products in development for the treatment, regeneration and repair of the spinal cord and brain.

Contact

Acorda Therapeutics, Inc.
Erica Wishner
Director, Corporate Communications
Cell: 914-282-0836
ewishner@acorda.com
or
Media:
Rooney and Associates Communications
Sean Leous
Cell: 917-715-3765





Page: 1 2 3 4 5 6 7

Related medicine technology :

1. Acorda Therapeutics Presents Fampridine-SR Data at ACTRIMS Meeting
2. Acorda Therapeutics to Host Analyst and Investor Reception
3. Acorda Therapeutics Presentation of Fampridine-SR Phase 3 Data Selected for Scientific Highlights Program at the American Academy of Neurology Meeting
4. Cell Therapeutics, Inc. Management to Discuss Todays Announcement of Interim Pixantrone Study Results
5. Halozyme Therapeutics Enhanze Technology Large Protein Molecule Therapeutic Clinical Trial Results Presented at the 34th Annual Meeting of the Controlled Release Society
6. CV Therapeutics Identifies Potential Anti-Diabetic Mechanism of Action for Ranexa
7. Fat Kills Cancer: Turning Stem Cells from Fat Tissue into Personalized, Cancer-Targeted Therapeutics
8. A 4-Week Therapy with Transition Therapeutics E1-I.N.T. Leads to Sustained Reductions in Blood Glucose Levels for 6 Months Post-treatment in Type 2 Diabetes Patients
9. Clinical Trial Suggests Bone Marrow Stem Cells Are Useful for Spinal Cord Injury; PrimeCell Therapeutics Provided Pre-Clinical Study
10. Opexa Therapeutics Reports Positive Top-line Data in Phase I/II Extension Trial with Tovaxin for Multiple Sclerosis
11. Orexigen Therapeutics to Present Data on Contrave Impact on Visceral Fat and Insulin Resistance at American Diabetes Association 67th Scientific Sessions in Chicago June 23
Post Your Comments:
(Date:1/6/2009)... In recent controlled studies condu...s , scientists found that the patented ingredient ...nly proven ingredient to increase levels of nitric...nitrate/nitrate (NOx) in human subjects. , , Ni...crease in blood flow to the skeletal muscles. Thi...
(Date:1/6/2009)...uary 6 , - Early ...on Until,December 2011 , - Expansion of th...Discovery in Ophthalmology , - Revised Comm...Sublicenses to a Third Party , ExonHit Th...inforcement,of its existing drug discovery collab...
(Date:12/30/2008)...RNewswire-USNewswire/ -- The Coalition for 21st Ce...on filed by Genentech, Inc. on December 5, 2008, s...offer diagnostic tests to physicians and patients....ests, would harm patient care and rests on flawed ...n,s mission is to encourage the research, developm...
(Date:12/17/2008)...in development and validation of non-animal altern... 17 MatTek Corporation today annou...(ESAC) endorsed the scientific validity of the Mod...vember meeting. ESAC concluded that the Modified ...y for the prediction of skin irritating and non-ir...
Breaking Medicine Technology:US Testing Proves Glyc'n Go(TM) Increases NO in the Blood Stream 2ExonHit Therapeutics Expands Strategic Collaboration With Allergan 2ExonHit Therapeutics Expands Strategic Collaboration With Allergan 3ExonHit Therapeutics Expands Strategic Collaboration With Allergan 4Coalition for 21st Century Medicine Issues Statement in Opposition of Genentech Petition to Restrict Lab Use of Diagnostic Tests for Physicians and Patients 2Coalition for 21st Century Medicine Issues Statement in Opposition of Genentech Petition to Restrict Lab Use of Diagnostic Tests for Physicians and Patients 3Coalition for 21st Century Medicine Issues Statement in Opposition of Genentech Petition to Restrict Lab Use of Diagnostic Tests for Physicians and Patients 4EpiDerm's Skin Irritation Test Fully Validated in European Union 2Empire Genomics and Reprogenetics Join Forces to Improve Preimplantation Genetic Diagnosis 28PGD 29 1249 1Empire Genomics and Reprogenetics Join Forces to Improve Preimplantation Genetic Diagnosis 28PGD 29 1249 2Empire Genomics and Reprogenetics Join Forces to Improve Preimplantation Genetic Diagnosis 28PGD 29 1249 3Pharsight Expands Global Consulting Services Teams 3640 1Pharsight Expands Global Consulting Services Teams 3640 2Pharsight Expands Global Consulting Services Teams 3640 3Memory Pharmaceuticals Announces Results for Phase 2a Trial of MEM 1003 in Alzheimers Disease 508 1Memory Pharmaceuticals Announces Results for Phase 2a Trial of MEM 1003 in Alzheimers Disease 508 2Memory Pharmaceuticals Announces Results for Phase 2a Trial of MEM 1003 in Alzheimers Disease 508 3Memory Pharmaceuticals Announces Results for Phase 2a Trial of MEM 1003 in Alzheimers Disease 508 4Study 3A Modafinil is effective in treating excessive sleepiness 3637 1Study 3A Modafinil is effective in treating excessive sleepiness 3637 2
...swire-FirstCall/ -- Vical,Incorporated today annou...e company,s Vaxfectin(TM) adjuvant elicited protec... (1 - 2 year old),nonhuman primates confirmed by c...ne year after vaccination, and sterilizing,immunit... no,detectable virus after challenge. In a separat...
...007 /PRNewswire-FirstCall/ -- Alexza,Pharmaceutica...he,49th Annual American Headache Society Meeting t...to(R) prochlorperazine (AZ-001),for the acute trea...n, "Efficacy and tolerability profile of AZ-001,(S...e headache",(Poster S-72), will be available for v...
Other Medicine Technology:Vaxfectin-formulated Measles DNA Vaccine Elicits Long-term,Protection and Sterilizing Immunity in Nonhuman Primates 2Vaxfectin-formulated Measles DNA Vaccine Elicits Long-term,Protection and Sterilizing Immunity in Nonhuman Primates 3Vaxfectin-formulated Measles DNA Vaccine Elicits Long-term,Protection and Sterilizing Immunity in Nonhuman Primates 4Alexza Pharmaceuticals to Present AZ-001 Phase IIb Clinical Data at,the American Headache Society Meeting 2
(Date:1/8/2009)...swire/ -- A study released this week showing that ...ultiple chronic diseases shines a much-needed spot...stem to one that focuses on primary and secondary ... the leader in disease prevention. , , (Logo:...TU129LOGO ) , , The study, conducted by Socia...
(Date:1/8/2009)...ember Tom Torlakson Introduces AB 89 , , SACRAM...Today, Lung Cancer Alliance-California (LCA-CA), h...11th District) for his continued leadership in int...ncer research. For the third consecutive year, le...being considered in the California Legislature. ...
(Date:1/8/2009)...emn hurtful comments, study suggests , ,... overestimate how strongly they would react to rac...hree percent of study participants at York Univers...eriment with a white person rather than a black on...s about the black person when he left the room. ,...
(Date:1/8/2009)...8 Hanger Orthopedic Grou... throughout the fourth quarter of 2008 it acquired...y Mountain Orthotic-Prosthetics Center, Riessen,s ...ast Orthotics & Prosthetics, and Orthopedic Re... patient care centers to existing markets in Maine...
Breaking Medicine News(10 mins):Health News:U.S. Preventive Medicine: Chronic Disease Study Demonstrates Need for Focus on Primary and Secondary Prevention 2Health News:Lung Cancer Alliance Applauds New Legislation Funding Lung Cancer Research 2Health News:Many Turn Blind Eye to Racism 2Health News:Hanger Orthopedic Group, Inc. Announces Six Acquisitions Totaling $8.9 Million of Annual Net Revenue 2
...ique Federale de Lausanne) and the CHUV (Lausanne ...ls in the hair follicle belong to the true multipo...nto many cell types needed for hair growth and fol...has documented its findings in an advance online p...
...ue of the journal Pediatrics says that the cavity ... of Cow's milk. Dr. Ruth A. Lawrence of the Unive...e Dr. William H. Bowen used rats to demonstrate th...se tooth decay faster than cow's milk. Baby mice d...
...of Multiple Sclerosis (MS), has been withdrawn fro...mplained of neurological disorders. The relationsh...Leukoencephalopathy (PML) is being researched by t...gnificant risk, it could be a serious setback for ...
...g a glassful of dangerous bacteria, not many will ...however did just that. He swallowed a cocktail of ...rial in origin rather than stress or lifestyle-rel... proved very useful as his colleague Robin Warren ...
Other Medicine News:Health News:Nobel For Ulcer-Defying Aussie Scientists 2
...RUP Laboratories is a national reference laborator...research and development. ARUP offers an extensive...sts in clinical and anatomic pathology. Owned by t...include more than half of the nation's university ...
...RUP Laboratories is a national reference laborator...research and development. ARUP offers an extensive...sts in clinical and anatomic pathology. Owned by t...include more than half of the nation's university ...
...RUP Laboratories is a national reference laborator...research and development. ARUP offers an extensive...sts in clinical and anatomic pathology. Owned by t...include more than half of the nation's university ...
...RUP Laboratories is a national reference laborator...research and development. ARUP offers an extensive...sts in clinical and anatomic pathology. Owned by t...include more than half of the nation's university ...
Medicine Products: